Ketogenic diet slows down mitochondrial myopathy progression in mice.
Level 5 - mechanism / opinion, no new human data
Animal model study (transgenic mice)
PubMed 20167576 · doi:10.1093/hmg/ddq076
What was done
Transgenic Deletor mice, an animal model of progressive late-onset mitochondrial myopathy driven by mitochondrial DNA (mtDNA) deletions and respiratory chain deficiency, were treated with a ketogenic diet (low glucose, high fat) administered either as a long-term pre-symptomatic regimen or a shorter-term post-symptomatic regimen. Effects on disease progression were evaluated using morphological, metabolomic, and lipidomic profiling.
What was found
The abstract reports qualitative outcomes without specific numerical values. Ketogenic diet treatment decreased the frequency of cytochrome c oxidase-negative muscle fibers and completely prevented mitochondrial ultrastructural abnormalities in skeletal muscle. The diet restored most altered plasma phospholipids, free amino acids, and metabolomic/lipidomic markers to wild-type levels, normalized liver lipid levels, and induced mitochondrial biogenesis. It did not significantly alter mtDNA quality or quantity.
Why it matters
These findings suggest that dietary modulation via a ketogenic diet can slow histological and metabolic progression in mitochondrial myopathy by promoting mitochondrial biogenesis rather than clearing mutant mtDNA, offering a potential therapeutic strategy for human late-onset mitochondrial disorders.
Limits
Findings are restricted to a transgenic mouse model and cannot be directly translated to human clinical efficacy or safety. The abstract does not provide quantitative data, exact sample sizes, dietary compositions, treatment durations, or functional/behavioral outcome metrics.
Cited by
- partial Shifting toward oxidative phosphorylation and ketone metabolism forces cells to upregulate mitochondrial biogenesis and electron transport chain proteins.